Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up
Induction ALK-TKIs provided a clinically efficient and well-tolerated therapeutic strategy in locally advanced ALK-positive NSCLC.
Authors
- Chao Zhang (ORCID: https://orcid.org/0000-0002-9891-0605)
- Jun‐Tao Lin (ORCID: https://orcid.org/0000-0002-0492-1021)
- Wen‐Zhao Zhong (ORCID: https://orcid.org/0000-0002-8917-8635)
- Zhen‐Bin Qiu (ORCID: https://orcid.org/0000-0003-4106-4011)
- Si‐Yang Maggie Liu (ORCID: https://orcid.org/0000-0002-3837-0758)
- Li‐Xu Yan (ORCID: https://orcid.org/0000-0002-5584-4265)
- Yuping Wu (ORCID: https://orcid.org/0000-0001-6399-9710)
- Zhiyong Chen (ORCID: https://orcid.org/0000-0001-5032-8280)
- Hao Sun (ORCID: https://orcid.org/0000-0002-9456-5824)
- Ben‐Yuan Jiang
- Yang Xue-ning
Institutions
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1097/cm9.0000000000003798
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00